Literature DB >> 28579413

Fertility in adult women with classic galactosemia and primary ovarian insufficiency.

Britt van Erven1, Gerard T Berry2, David Cassiman3, Geraldine Connolly4, Maria Forga5, Matthias Gautschi6, Cynthia S Gubbels7, Carla E M Hollak8, Mirian C Janssen9, Ina Knerr10, Philippe Labrune11, Janneke G Langendonk12, Katrin Õunap13, Abel Thijs14, Rein Vos15, Saskia B Wortmann16, M Estela Rubio-Gozalbo17.   

Abstract

OBJECTIVE: To study pregnancy chance in adult women with classic galactosemia and primary ovarian insufficiency. Despite dietary treatment, >90% of women with classic galactosemia develop primary ovarian insufficiency, resulting in impaired fertility. For many years, chance of spontaneous conception has not been considered, leading to counseling for infertility. But an increasing number of reports on pregnancies in this group questions whether current counseling approaches are correct.
DESIGN: Multicenter retrospective observational study.
SETTING: Metabolic centers. PATIENT(S): Adult women (aged >18 y) with confirmed classic galactosemia and primary ovarian insufficiency were included. INTERVENTION(S): Participants and medical records were consulted to obtain study data in a standardized manner with the use of a questionnaire. MAIN OUTCOME MEASURE(S): Conception opportunities, time to pregnancy, pregnancy outcome, hormone replacement therapy use, fertility counseling, and the participants' vision of fertility were evaluated. Potential predictive factors for increased pregnancy chance were explored. RESULT(S): Eighty-five women with classic galactosemia and primary ovarian insufficiency participated. Twenty-one women actively attempted to conceive or did not take adequate contraceptive precautions. Of these 21 women, nine became pregnant spontaneously (42.9%). This was higher than reported in primary ovarian insufficiency due to other causes (5%-10%). After a period of 12 months, a cumulative proportion of 27.8% of couples had conceived, which increased to 48.4% after 24 months and 61.3% after 27 months. Predictive factors could not be identified. A considerable miscarriage rate of 30% was observed (6 of 20 pregnancies). Although a substantial proportion of women expressed a child-wish (n = 28/53; 52.8%), the vast majority of participants (n = 43/57; 75.4%) considered conceiving to be highly unlikely, owing to negative counseling in the past. CONCLUSION(S): The pregnancy rate in women with classic galactosemia and primary ovarian insufficiency was higher than for women with primary ovarian insufficiency of any cause. This shifting paradigm carries significant implications for fertility counseling and potential application of fertility preservation techniques.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classic galactosemia; GALT deficiency; fertility; pregnancy; primary ovarian insufficiency

Mesh:

Year:  2017        PMID: 28579413     DOI: 10.1016/j.fertnstert.2017.05.013

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  12 in total

1.  Cryopreservation of ovarian tissue may be considered in young girls with galactosemia.

Authors:  Linn Salto Mamsen; Thomas W Kelsey; Erik Ernst; Kirsten Tryde Macklon; Allan Meldgaard Lund; Claus Yding Andersen
Journal:  J Assist Reprod Genet       Date:  2018-05-26       Impact factor: 3.412

Review 2.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.

Authors:  Mili Thakur; Gerald Feldman; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-20       Impact factor: 3.412

3.  Presentation, progression, and predictors of ovarian insufficiency in classic galactosemia.

Authors:  Allison B Frederick; Alison M Zinsli; Grace Carlock; Karen Conneely; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2018-05-02       Impact factor: 4.982

Review 4.  Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).

Authors:  Antonio La Marca; Elisa Mastellari
Journal:  J Assist Reprod Genet       Date:  2021-01-25       Impact factor: 3.412

5.  Intrafamilial oocyte donation in classic galactosemia: ethical and societal aspects.

Authors:  M Haskovic; W J Poot; R J T van Golde; S H Benneheij; E Oussoren; G M W R de Wert; A Krumeich; M Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2018-04-18       Impact factor: 4.982

Review 6.  Impact of pregnancy on inborn errors of metabolism.

Authors:  Gisela Wilcox
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

7.  The natural history of classic galactosemia: lessons from the GalNet registry.

Authors:  M E Rubio-Gozalbo; M Haskovic; A M Bosch; B Burnyte; A I Coelho; D Cassiman; M L Couce; C Dawson; D Demirbas; T Derks; F Eyskens; M T Forga; S Grunewald; J Häberle; M Hochuli; A Hubert; H H Huidekoper; P Janeiro; J Kotzka; I Knerr; P Labrune; Y E Landau; J G Langendonk; D Möslinger; D Müller-Wieland; E Murphy; K Õunap; D Ramadza; I A Rivera; S Scholl-Buergi; K M Stepien; A Thijs; C Tran; R Vara; G Visser; R Vos; M de Vries; S E Waisbren; M M Welsink-Karssies; S B Wortmann; M Gautschi; E P Treacy; G T Berry
Journal:  Orphanet J Rare Dis       Date:  2019-04-27       Impact factor: 4.123

Review 8.  Current and Future Treatments for Classic Galactosemia.

Authors:  Britt Delnoy; Ana I Coelho; Maria Estela Rubio-Gozalbo
Journal:  J Pers Med       Date:  2021-01-28

9.  Pilot study of classic galactosemia: Neurodevelopmental impact and other complications urge neonatal screening in Egypt.

Authors:  Magd A Kotb; Lobna Mansour; Christine William Shaker Basanti; Wael El Garf; Ghada I Z Ali; Sally T Mostafa El Sorogy; Inas E M Kamel; Naglaa M Kamal
Journal:  J Adv Res       Date:  2018-02-23       Impact factor: 10.479

Review 10.  Insights into the Pathophysiology of Infertility in Females with Classical Galactosaemia.

Authors:  Zaza Abidin; Eileen P Treacy
Journal:  Int J Mol Sci       Date:  2019-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.